Overview: HIV1 Genotyping Resistance TestIntroduction: The HIV1 Genotyping Resistance Test identifies HIV-1 drug resistance mutations to guide treatment, preventing disease progression. Aligned with 2023 DHHS guidelines, it uses PCR for high specificity, aiding in infectious disease screening. This test is critical for optimizing antiretroviral therapy, managing treatment failures, and improving outcomes in virology for patients with HIV/AIDS, particularly those with virologic failure.
Other Names: HIV 1 Resistance Assay, HIV Genotyping Test.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic accuracy.
Historical Milestone: HIV resistance testing began in the 1990s with antiretroviral therapy development. Genotyping assays improved in the 2000s, enhancing treatment optimization.
Purpose: Identifies HIV-1 drug resistance mutations, guides antiretroviral therapy, and monitors resistance in patients to prevent AIDS progression.
Test Parameters: 1. HIV 1 Drug Resistance Mutations
Pretest Condition: No fasting required. Collect plasma or serum at any time. Report history of HIV, treatment failures, or symptoms like weight loss, and list medications.
Specimen: 2-4 mL plasma (EDTA) or 2-5 mL serum (SST). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document weight loss, opportunistic infections, or history of HIV treatment failures. Include current medications, especially antiretrovirals, and adherence history.
Consent: Written consent required, detailing the tests purpose, resistance implications, and potential need for alternative antiretroviral therapy.
Procedural Considerations: Uses PCR to identify HIV-1 resistance mutations (e.g., M184V). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for treatment-experienced patients.
Factors Affecting Result Accuracy: Poor RNA quality, low viral load, or contamination can affect results. Antiretroviral therapy may suppress detectable mutations.
Clinical Significance: Identified resistance mutations guide selection of alternative antiretrovirals, improving treatment success. Negative results may indicate susceptibility to standard therapy.
Specialist Consultation: Consult an infectious disease specialist for result interpretation and antiretroviral therapy planning.
Additional Supporting Tests: HIV RNA, CD4 count, or phenotypic resistance testing to assess treatment response and disease status.
Test Limitations: Limited to HIV-1; low viral loads may limit mutation detection. Clinical correlation is needed.
References: DHHS HIV Guidelines, 2023; Clinical Infectious Diseases, Saag MS, 2022.
